Compare ADMA Biologics Inc (ADMA) vs D R Horton Inc (DHI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs D R Horton Inc — how do they compare? ADMA Biologics Inc trades at $9.02 (market cap $2.13B), while D R Horton Inc trades at $155.37 (market cap $44.16B). The key difference: D R Horton Inc is far larger — about 20.7× ADMA Biologics Inc's market cap, and D R Horton Inc pays a 1.16% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | DHI | |
|---|---|---|
Market Cap | $2.13B | $44.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $184.04 |
52-Week Low | $7.60 | $129.82 |
Enterprise Value | $2.20B | $48.87B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
D.R. Horton (DHI) trades at $155.72, down 1.8% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock faces headwinds from declining revenue and profit margins, with 2025 revenue dropping to $34.25B and net income falling to $3.59B. Recent earnings show mixed results with Q3 2025 missing expectations but Q4 2025 and Q1 2026 beating estimates. The company maintains strong operational cash flow of $3.42B despite a net cash outflow of $1.51B in 2025.
DHI presents a cautious opportunity with attractive valuation metrics (P/E 14.73, P/S 1.39) below sector averages, but faces significant housing market challenges. Analyst consensus leans neutral with 44% buy ratings and a $163.13 price target offering 4.8% upside. Key risks include housing market volatility, interest rate sensitivity, and competitive pressures in the homebuilding sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
